Magnetic resonance (MR) imaging was used to stage prostatic carcinoma in 81 patients with a proved diagnosis. MR imaging findings were correlated with histologic findings regarding the local extent of disease (37 patieNts) and the presence of nodal metastases (51 patients). Tumor nodules were detected in the peripheral zone (PZ) in 34 of 37 patients and were of low signal intensity compared with the signal of the PZ. Hemorrhage in the PZ represented a problem in tumor detection and in tumor volume measurement. When multiple criteria for local tumor spread were combined, MR imaging had a sensitivity of 72%, a specificity of 84%, and an accuracy of 78% in the differentiation of stage A or B from Stage C or D disease. Assessment of seminal vesicle invasion was more accurate than assessment of direct extracapsular spread. In five patients, microscopic invasion of the capsule (stage C) was classified as stage B with MR imaging; from a clinical standpoint, this should not affect patient treatment and prognosis. The MR imaging sensitivity in the detection of lymph node metastases was 69%, with a specificity of 95% and an accuracy of 88%. In this study MR imaging proved reliable in the comprehensive evaluation and staging of prostatic carcinoma.
Fifty-six consecutively transplanted renal allografts were prospectively evaluated with serial Doppler sonographic examinations. Thirty-eight episodes of transplant rejection in 32 patients (63% proved pathologically) and 24 episodes of acute tubular necrosis (ATN) in 24 patients were encountered. The Doppler spectral waveform was characterized by means of the pulsatility index (PI), systolic/diastolic ratio (SDR), diastolic/systolic ratio (SDR), diastolic/systolic ratio (DSR), and resistive index (RI). Accuracy was optimized with use of top normal values as follows: PI = 1.8, SDR = 4.0, DSR = 0.25, RI = 0.75. There were no significant differences in the indices for those patients undergoing rejection versus those with ATN. The sensitivity for predicting transplant rejection was adversely affected by the history of either ATN or a previous rejection episode in the same allograft. Comparison with concurrent radionuclide examinations revealed similar sensitivities for rejection with scintigraphy and sonography. Differentiation of ATN from rejection was more reliable with scintigraphy than with sonography.
Transvaginal (TV) and transabdominal (TA) sonography were compared in a prospective study. A total of 230 examinations (126 pelvic, 104 pregnancy) were performed on 215 patients, ranging in age from 14 to 80 years. The improved anatomic detail on TV scans yielded new information in 138 (60%) examinations and better visualization of pelvic structures in 51 (22%) examinations. There was no important difference in diagnostic information provided by the two imaging modalities in 36 (16%) cases, and TV images were worse in five (2%). The clinical diagnosis was altered on the basis of TV sonographic findings in 54 (24%) cases and confirmed with certainty in 166 (72%). Diagnostic problems posed by TA scanning were not resolved by TV scanning in ten (4%) instances. Statistical analysis indicated that TV scanning was significantly better than TA scanning in the visualization of gestational sac contents (P less than .005), detection of fetal heart motion (P less than .001), and evaluation of the endometrial canal in the retroverted or retroflexed uterus (P less than .001). TV scanning was significantly better than TA scanning in visualization of the ovaries in patients with uterine leiomyomas (P less than .005) but not significantly better in peri- and postmenopausal patients (P greater than .05).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.